Subscribe To

Price Alert Latest News Economic Calendar News

AADI / Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023

LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL. The details of the poster presentations are below: Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I) " Date and Time: Monday, April 17, 2023, 9:00 AM - 12:30 PM Session Title: Phase II and Phase III Clinical Trials in Progress Presentation Number: CT057 Title: "Synergistic anti-tumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts" Date and Time: Tuesday, April 18, 2023, 1:30 - 5:00 PM Session Category: Clinical Research Excluding Trials Session Title: Poster Combination Therapies for Cancer Presentation Number: 5484 Title: " Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations " Date and Time: Wednesday, April 19, 2023, 9:00 AM - 12:30 PM Session Category: Clinical Research Excluding Trials Session Title: Late-Breaking Research: Clinical Research 3 Presentation Number: LB288 Full session and meeting details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR. Read More

Demo Live Account See Partner Details

Content Topics

AADI

Bioscience

Present

Multiple

Posters

American

Association

Cancer

Research

aacr

Annual

Meeting

Stock

Posted: Apr 6 2023, 16:35

Author Name: PRNewsWire

AADI News

By Zacks Investment Research
August 9, 2023

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares t

By Seeking Alpha
June 29, 2023

Aadi Bioscience: High Risk/High Reward

Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is appr

By PRNewsWire
April 14, 2023

Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing

By PRNewsWire
April 6, 2023

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023

LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing a

By Seeking Alpha
March 6, 2023

Aadi Bioscience: Commercial Stage With Large Market In Label Expansion

AADI is a commercial stage company with a potential label expansion ahead. It is adequately funded, run by expert management, and has a major catalyst

By Zacks Investment Research
January 6, 2023

Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?

Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2

By Seeking Alpha
May 12, 2022

Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q1 2022 Results - Earnings Call Transcript

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Quan - VP, Business Developm

By GlobeNewsWire
April 28, 2022

Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

Company to hold conference call on May 12th at 8:30 am EDT Company to hold conference call on May 12th at 8:30 am EDT

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.